Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

Industry vs. FDA Regarding DTC Animation Study
Claims It's Unnecessary & Unscientific

On February 23, 2016, FDA announced that it proposed to study "Animation in Direct-to-Consumer Advertising" (read "Cute & Creepy DTC Drug Ad Mascots").

AbbVie, Astrazeneca, Eli Lilly, GSK, Merck, Regeneron Pharmaceuticals and other industry stakeholders have submitted comments to the FDA regarding this study.

This article summarizes several of these comments and FDA's responses to them.

Topics (partial list):
  • Why Now?
  • No Practical Utility
  • Animation is Protected Speech
  • Eeriness of Certain Types of Animation
  • The Uncanny Valley Theory
  • What's Animation Good For?
  • Another FDA Study: Character-Space-Limited Online Prescription Drug Communications

Download the full article (PDF file) here:
www.pharma-mkting.com/news/pmnews1505-article02.pdf

Further Reading


PMN1505-02
Issue: Vol. 15, No. 5: December 2016

Find other articles in related Topic Areas:

Vol 15, #5 Contents






Contact Information
Editor
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2016. Pharma Marketing Network. All rights reserved.